Inflammasome Therapeutics Reports Positive Six-Month Phase 2 Results for K8 in Geographic Atrophy

NEWTON, Mass.--(BUSINESS WIRE)--Inflammasome Therapeutics' K8 slowed GA lesion growth 54% and showed a 4.0-letter vision advantage at six months in Phase 2. Phase 3 planned.